William Blair & Co initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with an Outperform rating.

“We believe Nektar is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE